Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and met amplification.
Negative T790M Mutation and Met Amplification
DRUG: Glumetinib
ORR(Objective response rate), the sum ratio of partial response and complete response(determined by an Independent Radiology Review Committee (IRRC) according to RECIST Version 1.1), through study completion, an average of 1 year
ORR(Objective response rate, assessed as per investigators), the sum ratio of partial response and complete response(assessed as per investigators), through study completion, an average of 1 year|DOR(Duration of response), The time from the partial response and complete response of patient to patient progressive disease or death, The time from the date of first documented partial response or complete response to progressive disease or death, an average of 6 months|OS(Overall survival), The time from the patient first dose to death, Through study completion, an average of 1 year
To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and met amplification.